Drugs / 0.9% sodium chloride
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy6 trials | ||||||
| Phase 2/3 | NCT02088502 Comparator | Sep 2013 → Apr 2014 | — | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT02114346 Background | Jul 2013 → Feb 2014 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT05752279 Comparator | Mar 2024 → Jul 2026 overdue | diabetic ketoacidosis | The George Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT07437339 Comparator | Mar 2026 → Dec 2027 expected | — | Inova Health Care Services | Recruiting | No outcome recorded |
| Phase 4 | NCT02233985 Comparator | Aug 2013 → Feb 2017 | acute bronchiolitis, asthma | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| — | NCT04043598 Comparator | May 2022 → Jul 2027 expected | subarachnoid hemorrhage | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 0.9% Sodium-chloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04043598 ↗ |
| Route | Inhaled | “nebulized” NCT02233985 ↗ |